BridgeMD
New treatment option for Multiple Sclerosis, Relapsing-Remitting
Official title Multiple Sclerosis and the Effects of Ketogenic Diet Therapy
ClinicalTrials.gov ID: NCT06715436
What this study is testing
- What it's testing
- Multiple sclerosis (MS) is an inflammatory and immune-mediated neurological disease with multifactorial etiology. The specific etiopathogenetic mechanisms of MS are still unknown but it is clear that it results from a combination of genetic and environmental factors.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 60
You may be able to join if
- Diagnosis of relapsing-remitting MS (RRMS) or progressive MS (PMS)
- Age between 18 and 60 years
- BMI between 18.5 kg/m2 and 39.9 kg/m2
- If on disease-modifying drugs, stable for 6 months, or no use of drugs in the previous 6 months
- Ability to give verbal and written consent
You likely can't join if
- Patients actively engaged in a weight loss program or other specific diet (e.g. vegetarian, vegan); patients not willing to follow the assigned...
- Pregnancy or breastfeeding
- Relapse or cortisone treatment within 30 days before study entry
- Clinically relevant metabolic, progressive or malignant diseases
- Intake of \> 1 g/day of omega-3 fatty acid supplements
- Underweight (BMI\<18.5 kg/m2) or severe obesity
See the full eligibility criteria
- Diagnosis of relapsing-remitting MS (RRMS) or progressive MS (PMS)
- Age between 18 and 60 years
- BMI between 18.5 kg/m2 and 39.9 kg/m2
- If on disease-modifying drugs, stable for 6 months, or no use of drugs in the previous 6 months
- Ability to give verbal and written consent
- Patients actively engaged in a weight loss program or other specific diet (e.g. vegetarian, vegan); patients not willing to follow the assigned dietary pattern or patients with high adherence to MedDiet (MediLite score...
- Pregnancy or breastfeeding
- Relapse or cortisone treatment within 30 days before study entry
- Clinically relevant metabolic, progressive or malignant diseases
- Intake of \> 1 g/day of omega-3 fatty acid supplements
- Underweight (BMI\<18.5 kg/m2) or severe obesity
- Significant cognitive-cooperative impairment
- Insulin-dependent diabetes mellitus (type I)
- Weight loss greater than 5 kg within 2 months prior to study entry
- Diagnosis or suspicion of an eating disorder
- Kidney stones
- Oral anticoagulant therapy
- Known alcohol and drug abuse Telephonic interviews will be performed monthly to evaluate adherence to the dietary treatment and/or whether any changes in supplements use, physical activity, nutrition habits.
The study team makes the final eligibility decision.
Where it's taking place
- Pavia, Italy
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 60 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Pavia, Italy. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.